Searched for
BUY RATING CIPLA
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to ‘buy’Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a targe...
- Cipla stock in focus after Q2 PAT beats estimates. Should you buy, sell or hold?Cipla's shares are in focus as the company reported a 15% YoY increase in consolidated net profit to Rs 1,303 crore for Q2 2024. Revenue ro...
- UBS initiates coverage on 6 pharma stocks. Sun Pharma, Cipla among top buysThe report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a...
- Hot Stocks: Global brokerages see Airtel, Cipla delivering 10-15% return in next 1 yearICICI Prudential Life received an Equal Weight rating from Morgan Stanley, while Citigroup upheld its Buy rating for Bharti Airtel. Tata Co...
- Hot Stocks: Brokerage firms on Jindal Stainless, Cipla, Maruti Suzuki and Max HealthcareBernstein maintained an outperform rating on Cipla with a target price of Rs 1262. Cipla is a well-run organization. Blackstone will have t...
- Hot Stocks: Brokerages on UltraTech Cements, GAIL India, and CiplaGoldman Sachs maintained its buy rating on UltraTech Cements with a target price of Rs 8500. The global investment bank is seeing improved ...
- Hot Stocks: Brokerages on Bajaj Auto, Dr Reddy’s Laboratories, Tata Motors and Cipla post Q3 resultsEBITDA margin improved by 176 bps YoY to 24.2% despite soft Revlimid sales, mainly driven by an improvement in the mix. The net profit grew...
- Hot Stock: Brokerage view on SBI, Cipla and Titan Company post Q2 resultsMacquarie maintained an outperform rating on Cipla post Q2 results and increased the target price to Rs 1265 from Rs 1220. It was an operat...
- Brokerages see up to 20% upside in Cipla post Q1 results; time to buy?Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding th...
- Brokerages raise targets on CiplaCipla’s shares hit a record high of Rs 814.45 on Monday before ending at Rs 795.65, up 9.2 per cent from the previous close. Cipla reported...
- Stock pick of the week: What has made Cipla a favourite of analystsDue to the recent price correction, the risk-reward ratio of Cipla has turned favourable. Despite the tough environment, the company is tak...
- HSBC maintains ‘buy’ rating on Cipla“Assuming 10-15% market share and price discount of 25-30%, gSeretide could be a USD25-35m annual sales opportunity for Cipla,” said HSBC.
- Analysts bet on Cipla as acquisitions expected to boost company's growthAcquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.
- RBS recommends a 'Buy' rating on CiplaRBS has recommended a 'Buy' rating on Cipla with a target price of 360.
Load More
